| Product Name |
Murine Leukemia Virus (MLV) Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Variant |
| Catalog Number |
EG-345 |
| Description |
Murine leukemia virus (MLV) particles pseudotyped with SARS-CoV-2 spike glycoprotein (Wuhan-Hu-1, GenBank: QHD43416.1), stabilized as a trimer (HexaPro variant) with mutations (RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P) to maintain an antigenically optimal prefusion conformation, produced in HEK293T cells, purified by ultracentrifugation, expressing EGFP as a reporter. |
| Mutations |
RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P |
| Source |
HEK293T cells |
| Reporter |
EGFP |
| Applications |
- Screening SARS-CoV-2 neutralizing antibodies
- Assessing vaccine efficacy
|
| Titer |
>1 × 107 RFU/mL or >1 × 105 TU/mL |
| Storage |
-80°C |
| Shipping |
Dry ice |
| References |
- Millet, J. K., & Whittaker, G. R. (2016). Murine leukemia virus (MLV)-based coronavirus spike-pseudotyped particle production and infection. Bio-Protocol, 6(23), e2035. doi:10.21769/BioProtoc.2035.
- Giroglou, T., et al. (2004). Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. Journal of Virology, 78(17), 9007–9015. doi:10.1128/JVI.78.17.9007-9015.2004.
|
|